Skip to main content

Abstract

The efficacy of the probiotic strain, Bacillus coagulans Unique IS2 in the treatment of Irritable Bowel Syndrome (IBS) was evaluated in children. A total of 141 children of either sex in the age group 4-12 years, diagnosed with IBS according to the Rome III criteria, participated in the double-blind randomised controlled trial. Children received either B. coagulans Unique IS2 chewable tablets or placebo once daily for eight weeks followed by a two week follow-up period. Reduction in pain intensity as well as other symptoms associated with Irritable Bowel Syndrome like abdominal discomfort, bloating, distension, sense of incomplete evacuation, straining at stool, urgency of bowel movement, passage of gas and mucus, and bowel habit satisfaction were assessed. B. coagulans Unique IS2 treated group showed a greater reduction in pain scores as evaluated by a weekly pain intensity scale. There was a significant reduction (P<0.0001) in pain intensity in the probiotic treated group (7.6±0.98) as compared to the placebo group (4.2±1.41) by the end of the treatment period (8 weeks). There was also a significant improvement in stool consistency as well as reduction in abdominal discomfort, bloating, staining, urgency, incomplete evacuation and passage of gas. Bowel habit satisfaction and global assessment of relief was also observed in the B. coagulans Unique IS2 treated group as compared to the placebo group. This study demonstrates the efficacy of B. coagulans Unique IS2 in reducing the symptoms of Irritable Bowel Syndrome in children in the age group of 4-12 years.

Keywords: B. coagulans Unique IS2; irritable bowel syndrome; probiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bacillus coagulans SNZ-1969Global Relief AssessmentBeneficial
Moderate
Bacillus coagulans SNZ-1969Improved Bowel Habit SatisfactionBeneficial
Moderate
Bacillus coagulans SNZ-1969Improved Stool ConsistencyBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced Abdominal DiscomfortBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced BloatingBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced Pain Intensity in Irritable Bowel SyndromeBeneficial
Large
Bacillus coagulans SNZ-1969Reduced Passage of GasBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced Sense of Incomplete EvacuationBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced StrainingBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced Urgency of Bowel MovementsBeneficial
Moderate
Bacillus coagulans Unique IS-2Improved Stool ConsistencyBeneficial
Moderate
Bacillus coagulans Unique IS-2Reduced Abdominal DiscomfortBeneficial
Moderate
Bacillus coagulans Unique IS-2Reduced BloatingBeneficial
Moderate
Bacillus coagulans Unique IS-2Reduced Pain IntensityBeneficial
Large
Bacillus coagulans Unique IS-2Reduced Passage of GasBeneficial
Moderate
Bacillus coagulans Unique IS-2Reduced Sense of Incomplete EvacuationBeneficial
Moderate
Bacillus coagulans Unique IS-2Reduced StrainingBeneficial
Moderate
Bacillus coagulans Unique IS-2Reduced Urgency of Bowel MovementsBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.